Inhibition of Trx-1 and G6PD in combination with inhibition of glycolysis using 2-deoxy-D-glucose (2DG) resulted in a substantial anti-tumor effect in CRC xenografts in vivo. This evidence concerns the gene G6PD and colorectal carcinoma.